Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwMyeloma 2017 | The future of immunotherapy in multiple myeloma

Hearn Jay Cho, Ivan Borrello and Tuna Mutis • 18 Oct 2017
iwMyeloma 2017
Multiple Myeloma Antibodies Checkpoint inhibitors Vaccines

There is a plethora of therapies available for multiple myeloma (MM). In this insightful panel discussion at the Myeloma 2017 meeting in Edinburgh, UK, Ivan Marques Borrello, MD from John Hopkins School of Medicine, Baltimore, MD, Hearn Cho, MD, PhD from Mount Sinai School of Medicine, New York, NY and Tuna Mutis, MD, PhD from the VU University Medical Center, Amsterdam, Netherlands, discuss the current state of immunotherapy for MM and what the future holds. They share their thoughts on combination therapies, creating more broadly applicable therapies, checkpoint inhibitor trials and bispecific antibodies.

More from Hearn Jay Cho

10:01
Novel targets in 2022
Charlotte Pawlyn et al. • 26 Mar 2022

More from Ivan Borrello

15:05
The role of the microenvironment in multiple myeloma
Bruno Paiva et al. • 9 Sep 2018
2:18
Adoptive T-cell therapy for the treatment of MM
Ivan Borrello • 22 Jun 2017
1:07
Using vaccines to impart a long-term response in lenalidomide-treated MM
Ivan Borrello • 22 Jun 2017
9:13
Myeloma 2016: Panel discussion on gene modified T-cells
Edward Stadtmauer et al. • 22 Apr 2016

More from Tuna Mutis

0:57
Focusing on allogeneic CAR T-cell therapies for myeloma
Tuna Mutis • 1 Apr 2022
0:52
Highlights from ICLE 2022
Tuna Mutis • 1 Apr 2022
1:09
Current research on anti-CD38 CAR T-cell therapies
Tuna Mutis • 1 Apr 2022
2:15
Relapsing from CAR T-cells in multiple myeloma
Tuna Mutis • 1 Apr 2022

Related Videos

3:54
Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial
Roberto Mina • 23 Apr 2024
1:41
CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma
Eden Biltibo • 15 Apr 2024
0:36
The recent expanded FDA approval of cilta-cel and ide-cel into earlier lines of myeloma treatment
Sergio Giralt • 16 Apr 2024
1:48
Tackling underrepresentation of minorities in CAR-T clinical trials
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals